Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer

NCT00061906 ↗

Phase 2 Completed 25 enrolled Ohio State University Comprehensive Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have progressive metastatic differentiated thyroid cancer.

Timeline

Start: 2003-01
Primary completion: 2006-06
Completion: 2006-06

Outcome

Missed primary endpoint

paper Twenty-three of 32 patients experienced progressive disease or stopped therapy due to toxicity, thus fulfilling the intent-to-treat study endpoint for celecoxib failure. PMID 16522694 ↗

Publications

Results Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006 Jun;91(6):2201-4. doi: 10.1210/jc.2005-2498. Epub 2006 Mar 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	400 mg	Oral